A phase 3, randomised, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of once-weekly PB-119 as add-on to metformin in patients with type 2 diabetes in China

被引：0
|
作者：
Xu, M. [1 ]
机构：
[1] Pegbio Biomed Co, Suzhou, Peoples R China
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
638
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [1] A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of 12 Once-Weekly Subcutaneous Doses of PB-119 to Patients with Type 2 Diabetes Mellitus as Monotherapy
    Xu, Min
    DIABETES, 2020, 69
  • [2] Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study
    Cai, Xiaoling
    Ji, Linong
    Yuan, Mingxia
    Ma, Jianhua
    Bian, Fang
    Li, Sheli
    Pang, Wuyan
    Yan, Shuang
    Zhou, Huimin
    Hou, Minghui
    Li, Wenhui
    Jia, Ying
    Liu, Li
    Ding, Ke
    Xu, Michael
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 51
  • [3] Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes inadequately controlled with metformin and dapagliflozin: a randomised, double-blind, and placebo-controlled study
    Cho, Y.
    Kim, K. -S.
    Lee, B. -W.
    Hong, J.
    Yu, J.
    Lim, S.
    Kim, Y.
    Lee, C.
    Kim, S.
    Kwak, S.
    Lee, W.
    DIABETOLOGIA, 2024, 67 : S322 - S323
  • [4] Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
    Taskinen, M. -R.
    Rosenstock, J.
    Tamminen, I.
    Kubiak, R.
    Patel, S.
    Dugi, K. A.
    Woerle, H. -J.
    DIABETES OBESITY & METABOLISM, 2011, 13 (01): : 65 - 74
  • [5] Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
    Lingvay, Ildiko
    Catarig, Andrei-Mircea
    Frias, Juan P.
    Kumar, Harish
    Lausvig, Nanna L.
    le Roux, Caret W.
    Thielke, Desiree
    Viljoen, Adie
    McCrimmon, Rory J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 834 - 844
  • [6] Efficacy and Safety of Once-Weekly PB-119 Monotherapy vs. Placebo in Chinese Patients with Type 2 Diabetes in a Randomized Controlled Trial
    Xu, Min
    Liang, Ruifang
    DIABETES, 2023, 72
  • [7] Review of the Safety and Efficacy of Linagliptin as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
    Rendell, Marc
    Chrysant, Steven G.
    POSTGRADUATE MEDICINE, 2011, 123 (04) : 183 - 186
  • [8] Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial
    Ji, Linong
    Dong, Xiaolin
    Li, Yiming
    Li, Yufeng
    Lim, Soo
    Liu, Ming
    Ning, Zu
    Rasmussen, Soren
    Skjoth, Trine Vang
    Yuan, Guoyue
    Eliaschewitz, Freddy G.
    DIABETES OBESITY & METABOLISM, 2021, 23 (02): : 404 - 414
  • [9] Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
    Ahren, Bo
    Masmiquel, Luis
    Kumar, Harish
    Sargin, Mehmet
    Karsbol, Julie Derving
    Jacobsen, Sanja Hald
    Chow, Francis
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (05): : 341 - 354
  • [10] Efficacy and Safety of Once-Weekly Semaglutide vs. Once-Daily Sitagliptin as Add-On to Metformin in Subjects with Type 2 Diabetes (SUSTAIN China MRCT): A 30-Week Double-Blind, Phase 3a, Randomised Trial
    Ji, Linong
    Dong Xiaolin
    Eliaschewitz, Freddy
    Li, Yiming
    Li, Yufeng
    Lim, Soo
    Liu, Ming
    Zu, Ning
    Rasmussen, Soeren
    Skjoeth, Trine V.
    Yuan, Guoyue
    Huang, Yu-Yao
    DIABETES, 2020, 69
12345